US20120193264A1 - Production of a biopharmaceutical product - Google Patents

Production of a biopharmaceutical product Download PDF

Info

Publication number
US20120193264A1
US20120193264A1 US13/499,738 US201013499738A US2012193264A1 US 20120193264 A1 US20120193264 A1 US 20120193264A1 US 201013499738 A US201013499738 A US 201013499738A US 2012193264 A1 US2012193264 A1 US 2012193264A1
Authority
US
United States
Prior art keywords
pouch
replacement
support
inherent means
biopharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/499,738
Other languages
English (en)
Inventor
Magali Barbaroux
Samuel Dorey
Mareva Gueneron
Oscar Reif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sartorius Stedim FMT SAS
Original Assignee
Sartorius Stedim Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sartorius Stedim Biotech SA filed Critical Sartorius Stedim Biotech SA
Assigned to SARTORIUS STEDIM BIOTECH S.A. reassignment SARTORIUS STEDIM BIOTECH S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARBAROUX, MAGALI, DOREY, SAMUEL, GUENERON, MAREVA, REIF, OSCAR
Publication of US20120193264A1 publication Critical patent/US20120193264A1/en
Assigned to SARTORIUS STEDIM FMT SAS reassignment SARTORIUS STEDIM FMT SAS MERGER (SEE DOCUMENT FOR DETAILS). Assignors: SARTORIUS STEDIM BIOTECH
Assigned to SARTORIUS STEDIM FMT SAS reassignment SARTORIUS STEDIM FMT SAS CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 031974 FRAME 0578. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Assignors: SARTORIUS STEDIM BIOTECH
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/14—Bags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis

Definitions

  • the invention relates to the production of a biopharmaceutical product, and its purpose is more particularly a process for the production of a biopharmaceutical product in and with a pouch unit that is selected for this purpose, such a pouch unit being specially designed for implementing this process, such a pouch unit before the filling of contents, and such a pouch unit that is filled with the finished biopharmaceutical product, and, finally, a unit that comprises, in the first place, a pouch unit, and, in the second place, means for activation of the inherent means of support and replacement of the pouch unit.
  • Biopharmaceutical product is defined as a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product, or more generally a product that is designed to be used in the medical field. In the context of the invention, this biopharmaceutical product has the characteristic of being in a substantially liquid or paste form.
  • Such a device first of all comprises a pouch unit that includes, in the first place, the pouch in question itself, defining an inside space that can contain the biopharmaceutical product, limited by a wall, continuous as a whole, made of a film of flexible plastic material that is airtight, and non-degradable, and that can be in direct contact by its inside face with the biopharmaceutical product, and can contain it, and, in the second place, combined with the pouch, at least one port, and, if necessary, at least one functional device such as a device for mixing, aeration, . . . .
  • Such a device can next comprise, if necessary, an outside rigid container for receiving the pouch unit in its inherent inside space.
  • “Production process” is defined as one or more phases of a physical-chemical-biological process during which the biopharmaceutical product is partly or completely manufactured to reach the finished state that allows its immediate use or a semi-finished state that allows a subsequent use.
  • Such a phase consists in, for example, the addition of one or more components using at least one port of the pouch unit, or in a mixture, an aeration, a filtration, a reaction, a heating or a cooling (with this list not being exhaustive), using at least one suitable functional device with which the pouch unit is provided.
  • “Biopharmaceutical product” is defined both as the biopharmaceutical product in the finished state and an intermediate product of the process for producing the latter.
  • a pouch unit that has a pouch whose two large walls are directly joined to one another is known. Once expanded, such a pouch has a limited volume and remains relatively thin, which justifies the fact that this pouch is often called “pillow” pouch or “2D” pouch (with D meaning dimensions).
  • a 3D pouch with gussets that comprises two end walls and one side wall that can be folded flat or deployed unfolded, welded to one another, with the volume then able to be at least 50 liters, up to 3,000 liters, and even more, is also known.
  • Such a 3D pouch is described in the document WO00/04131 or is marketed by the company Sartorius Stedim Biotech under the trademark FLEXEL® 3D.
  • the wall of the pouch performs a unique mechanical function that consists in, on the one hand, containing the substantially liquid or pasty biopharmaceutical product by absorbing the forces that result from its presence in the inside space of the pouch and its direct contact with its inside face, and, on the other hand, to support the at least one port and, if necessary, the at least one functional device.
  • the production of the biopharmaceutical product in the pouch unit uses or generates one or more bodies that are functionally intrinsic to the biopharmaceutical product within the scope of its production, i.e., being part of the biopharmaceutical product or a component of the latter or used for the production of the biopharmaceutical product or generated upon this occasion.
  • a body is qualified here as an incident body.
  • Such an incident body is such that:
  • biopharmaceutical product Being and not being “substantially” within the biopharmaceutical product means, respectively, in a very predominant and quantitatively prominent way, that the incident body is located and is not located within the biopharmaceutical product.
  • Such a body is termed incident relative to the biopharmaceutical product, because it is necessary to understand that the weight and the volume of the body are low to very low and even minute relative to the weight and the volume of the biopharmaceutical product.
  • Such a body is solid and small in size or liquid (including paste form); in any case, it is not gaseous.
  • Solid is defined as the fact of exhibiting a certain cohesion or a certain consistency and being neither liquid nor gaseous.
  • a toxin or a microorganism is part of the definition of solid.
  • Small in size is defined as a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
  • Such a body if it is solid, is individual or broken into a number, more specially a large number, of units or pieces. This is why, even though such a body is solid, it is possible to describe a biopharmaceutical product that contains it within itself as being in a substantially liquid or paste form. Consequently, a biopharmaceutical product that is in a “substantially” liquid or paste form means, in a very predominant and quantitatively prominent way, that the biopharmaceutical product is in liquid or paste form, even when it comprises such a solid body within itself.
  • Such an incident body can be varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
  • a device for introduction or evacuation is, for example, a port that can be closed or open based on the requirements.
  • “Patches” that are designed to be applied on the skin of an individual comprising one or more active substances that are released once the patch is applied to the skin for dermal or transdermal use are known. Reference can be made to, for example, the documents EP-A-0278473, U.S. Pat. No. 4,557,723, U.S. Pat. No. 4,638,043, U.S. Pat. No. 4,752,478 and US-A-2009/0142388.
  • Oxygen absorbers that are designed quite specially for the packaging of food products for the purpose of limiting or preventing their oxidation and thus to allow a more significant preservation period are known.
  • Such an oxygen absorber can come in the form of a packet or a pellet or a label that is introduced into the packaging beside the food product or can be included or combined with the wall of the packaging itself. It is possible to refer to, for example, the documents WO 2008/084231 and WO 2005/033676. In the same way, moisture absorbers, corrosion inhibitors, absorbers of bad odors, gas emitters, and antibacterial agents are known.
  • Such devices are well suited to their own purpose but cannot be applied in the case of the production of a biopharmaceutical product, as it was defined above, in particular because the product concerned is in solid form and not in liquid or paste form, and/or because the purpose of the device is the preservation and not the production of the product, and/or because the body concerned is in gaseous form and not solid or liquid (including paste form), and/or because the device does not act directly on the product concerned but on its environment.
  • the purpose of the invention is therefore to meet this requirement.
  • the invention has as its object a process for the production of a biopharmaceutical product in substantially liquid or paste form by a physical-chemical-biological production process, in which:
  • the solid incident body is individual or is broken into a number, more specially a large number, of units or pieces.
  • the solid incident body is of a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size.
  • the pouch unit is used in such a way that the incident body is moved, in a substantial way, between the biopharmaceutical product and the inherent means of support and replacement, in the direction that goes from the first to the second or in the direction that goes from the second to the first.
  • the inherent means of support and replacement is functionally active in response to the value taken on by at least one physical-biological-chemical condition of the contents of the pouch or in response to the value taken on by the variation of such a physical-biological-chemical condition or in response to a dedicated activation operation of a physical, biological, or chemical nature.
  • the inherent means of support and replacement before filling with contents, is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
  • the inherent means of support and replacement is not loaded with an incident body, or, in contrast, is substantially loaded with the incident body.
  • the invention has as its object a pouch unit that is specially designed for the implementation of the process for the production of a biopharmaceutical product in the substantially liquid or paste form that was just described, including a pouch that defines an inside space that can contain the biopharmaceutical product during its production process, limited by a continuous wall that is flexible, airtight, and non-degradable, and that can be in direct contact by its inside surface with the biopharmaceutical product, and can contain it, and, combined with the pouch, at least one port, if necessary at least one functional device.
  • the pouch unit incorporates an inherent means of support and replacement:
  • the pouch unit is implemented such that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and such that, with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch itself and is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
  • the inherent means of support and replacement consists of or comprises a membrane or a coating or a surface treatment of the wall of the pouch or at least one port or functional device, or a body of support and replacement, or a compartment of support and replacement.
  • the inherent means of support and replacement is located toward the inside surface of the wall of the pouch or at least one port or functional device that forms it or integrates it.
  • the inherent means of support and replacement is located on the entire surface or only a portion of the surface of a face of the pouch or at least one port or functional device that forms it or integrates it by then being either located on or distributed over this surface.
  • the inherent means of support and replacement is located at least in the lower part or at least in the lower part and in the median part of the unit.
  • an inherent means of support and replacement has a surface area for replacement with the contents of the pouch during the process for the production of the biopharmaceutical product that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of the inside face of the wall of the pouch or at least one port or functional device that forms it or integrates it, and that is in direct contact with the contents of the pouch, in particular as a result of the composition of the inherent means of support and replacement, or the wall of the pouch or at least one port or functional device that forms it or in which it is integrated or the configuration of the inherent means of support and replacement on the wall of the pouch or at least one port or functional device that forms it or in which it is integrated.
  • the pouch is a 2D pouch or a 3D pouch.
  • the invention also has as its object a pouch unit before filling with contents in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
  • the invention also has as its object a pouch unit that is filled with finished biopharmaceutical product, in which, according to the embodiments, the inherent means of support and replacement is not loaded with the incident body or, in contrast, is substantially loaded with the incident body.
  • the invention also has as its object a unit that comprises, in the first place, a pouch unit as it was described in which the inherent means of support and replacement is functionally active as a consequence of a dedicated activation operation, and, in the second place, means for activation of the inherent means of support and replacement of a physical, biological or chemical nature.
  • the activation means consist of the biopharmaceutical product that is in the inside space of the pouch unit and that has properties that can activate the inherent means of support and replacement.
  • the activation means are located outside of the pouch unit.
  • FIG. 1 is a diagrammatic perspective view of a 3D pouch with gussets that is part of a pouch unit that is specially designed for implementing a process for the production of a biopharmaceutical product in a substantially liquid or paste form according to the invention, with the pouch unit incorporating an inherent means of support and replacement, whereas during the process for the production of biopharmaceutical product, at least one incident body is used or generated and whereas the pouch unit is implemented in such a way that the inherent means of support and replacement is in direct physical contact with the contents of the pouch and in such a way that with the inherent means of support and replacement being functionally active, the incident body passes substantially between one and the other of the inherent means of support and replacement and within the contents of the pouch in such a way that the incident body is substantially loaded on the inherent means of support and replacement when it is not or should not be substantially within the biopharmaceutical product.
  • FIG. 2 illustrates, on the one hand, the relative arrangement of the inherent means of support and replacement relative to the pouch unit and to the contents of the pouch, and, on the other hand, the two functions of the inherent means of support and replacement.
  • FIGS. 3 to 13 are eleven views, in transverse cutaways, on a larger scale illustrating different possible embodiments of the inherent means of support and replacement that the pouch unit incorporates.
  • the description refers to the definitions provided above that involve the biopharmaceutical product P, its substantially liquid or paste form, the process for the production of such a biopharmaceutical product P, a 2D pouch or a 3D pouch, the incident body C, and, for this product, the qualification of solid and small size, etc.
  • a pouch unit 1 as shown in FIG. 1 is part of a device that is designed for the production of a biopharmaceutical product P, i.e., a product that is obtained from biotechnology—culture media, cellular cultures, buffer solutions, artificial nutrition liquids, blood products and derivatives of blood products—or a pharmaceutical product or more generally a product that is designed to be used in the medical field.
  • a biopharmaceutical product P has the characteristic of being in a substantially liquid or paste form, being totally or at least in a very predominant and quantitatively prominent way, in liquid or paste form, even when, if necessary, it comprises within itself a solid body in a very small quantity.
  • the production of the biopharmaceutical product P consists of one or more phases of a physical-chemical-biological process during which the biopharmaceutical product P is completely or partly manufactured before reaching the finished state that makes possible its direct use or a semi-finished stage that makes possible a subsequent use, such as, for example, an addition of one or more components, a mixture, an aeration, a filtration, a reaction, a heating or a cooling . . . .
  • one or more incident body(ies) C is/are used or generated (which includes the case where it is used and generated).
  • Such an incident body C is solid and small in size or is liquid (including paste form) and, at at least one time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P while at at least one other time or stage of the production process, it is not or should not be within the biopharmaceutical product P, in that in a very predominant and quantitatively prominent way, the incident body C, respectively, is located and is not located within the biopharmaceutical product P.
  • Such an incident body C has a small to very small and even minute weight and volume relative to the weight and volume of the biopharmaceutical product P.
  • Such an incident body C is solid and small in size, having a certain cohesion or a certain consistency, or is liquid (including paste form), in any case not being gaseous, and having, if it is solid, a dimension on the order of, or less than, or significantly less than, a millimeter, down to molecular size, where this is understood for each unit or piece.
  • incident body C if it is solid, is individual or broken into a number, more specially a large number, of units or pieces.
  • Such an incident body C is varied, concerning its substance, its nature, its structure, its composition, its function, its origin, its properties, its usefulness or its harmfulness . . . . It may involve, for example, a body that falls within the final composition of the biopharmaceutical product P or falls within its initial composition or active ingredients or wastes or reaction by-products or impurities or a catalyst, activator, regulator or a toxin or an antibiotic or a body that acts on one or more physical-biological-chemical conditions of the biopharmaceutical product P or one or more physical-biological-chemical conditions that prevail(s) in the pouch or antibody, cells, or bacteria.
  • the pouch unit 1 includes a pouch 2 that, according to the embodiments, is a so-called 3D pouch with gussets as shown in FIG. 1 , or a so-called 2D pouch, not shown.
  • the pouch 2 defines an inside space 2 a, able to contain the contents of the pouch during the production of the biopharmaceutical product P, in particular the biopharmaceutical product P itself, during its production.
  • the pouch 2 is limited by a wall 3 , continuous as a whole, made of a plastic film. It is flexible, airtight and non-degradable.
  • the film that forms the wall 3 is single-material or not, single-layer or not.
  • The—or each of the—constituent material(s) of the film is/are selected from among the materials that satisfy the above-mentioned requirements, as well as the mechanical strength requirements.
  • the wall 3 has an outside face 3 a and an inside face 3 b. “Outside” is defined as what is not located in the pouch 2 , and “inside” is defined as what is located in the pouch 2 and limits the inside space 2 a.
  • the pouch 2 can be in direct contact by its inside face 3 b with the contents of the pouch 2 , in particular the biopharmaceutical product P, and can contain it.
  • the pouch 2 is arranged to support at least one port 4 , for example a port for filling and a port for emptying.
  • “Port” is defined as any means of communication between the outside and the inside of the pouch 2 , which is open at one or more times or in one or more stages when the communication is desired, or, if not, is sealed.
  • At least one functional device 5 such as a device for mixing, aeration, filtration, measuring (whereby this list is not exhaustive), and comprising a suitable element, such as a mixing propeller, aerator, filter, probe (whereby this list is not exhaustive), is combined in general, and if necessary, with the pouch 2 .
  • a suitable element such as a mixing propeller, aerator, filter, probe (whereby this list is not exhaustive)
  • Such an element is at least partly placed in the inside space 2 a of the pouch 2 .
  • the at least one port 4 or functional device 5 has, in line with the wall 3 of the pouch 2 , an inside face that is located in the pouch 2 .
  • the pouch unit 1 at least during the process for the production of the biopharmaceutical product P, is arranged to have a lower part 2 b, an upper part 2 c, and a median part 2 d.
  • the pouch 2 comprises one or a number of ports 4 for filling in the upper part 2 c (such as the port 4 shown in FIG. 12 ) and a port 4 for emptying into the lower part 2 b, and a functional device 5 for mixing in the lower part 2 b ( FIG. 13 ).
  • the pouch 2 comprises one or a number of ports 4 for filling in the upper part 2 c (such as the port 4 shown in FIG. 12 ) and a port 4 for emptying into the lower part 2 b, and a functional device 5 for mixing in the lower part 2 b ( FIG. 13 ).
  • Such an embodiment does not exclude others.
  • the device that is designed for the production of the biopharmaceutical product P can comprise, if necessary, an outside rigid container for receiving the pouch unit 1 in its inherent inside space.
  • the pouch unit 1 incorporates an inherent means of support and replacement 6 .
  • “Incorporating” means that the means 6 forms a cohesive, in particular an inseparable, unit with the pouch unit 1 .
  • “Inherent” means that the functions of support and replacement that describe the means 6 belong to the latter and characterize it.
  • the inherent means of support and replacement 6 is formed by or integrated in the wall 3 of the pouch 2 or in at least one port 4 or functional device 5 . In so doing, the inherent means of support and replacement 6 is able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 , in particular the biopharmaceutical product P.
  • the inherent means of support and replacement 6 is arranged in such a way as to be functionally capable of being able to be loaded with an incident body C and to make possible the passage of this incident body C between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 .
  • the means 6 is therefore able to ensure a first function that consists in being able to be loaded with the incident body C and also a second function that consists in making possible the passage of the incident body C between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 , in particular the biopharmaceutical product P.
  • “Loaded” means that the incident body C is carried or captured by or held or located on or assimilated or adsorbed or absorbed by the inherent means of support and replacement 6 in such a way that under normal conditions and without other intervention, it cannot disseminate or be disseminated, at least substantially, outside of the inherent means of support and replacement 6 or its immediate proximity.
  • Passage means that the incident body C migrates and is moved from the inherent means of support and replacement 6 or its immediate proximity to the biopharmaceutical product P or to one or more of the components of the latter, in the direction that goes from the first to the second (arrows F 1 , FIG. 2 ) or from the second to the first (arrows F 2 , FIG. 2 ). In the case where there are two (or more) incident bodies C 1 and C 2 , they can “pass” in the two directions (arrows F 3 and F 4 , FIG. 2 ).
  • the inherent means of support and replacement 6 is functionally active per se, in particular permanently or as a consequence of a dedicated activation operation, in particular from a given time.
  • the process for the production of the biopharmaceutical product P is such that a pouch unit 1 is used as it was described above, and the biopharmaceutical product P, not totally finished, or components of the latter, and the pouch 2 , then in particular empty, is filled by thus constituting the contents of the pouch 2 .
  • the production process is implemented in and with the pouch unit 1 , and during this process, the incident body C is used or generated, or the latter is used or generated.
  • the production process can consist in adding a component, for example, in finely-divided solid form—from the outside of the pouch 2 and via a port 4 —to the contents in liquid or paste form that are already in the pouch 2 for having been placed there previously and in mixing the whole by means of a functional device 5 , here a mixer.
  • a functional device 5 here a mixer.
  • the pouch unit 1 is totally filled, or it is only partially filled, in its lower part 2 b or at least in the lower part 2 b and in all or part of the median part 2 d.
  • FIG. 2 which illustrates, on the one hand, the relative arrangement of the inherent means of support and replacement 6 relative to the pouch unit 1 and to the contents of the pouch 2 , and, on the other hand, the two functions of the inherent means of support and replacement 6
  • the pouch unit 1 is used in such a way that the inherent means of support and replacement 6 that is submerged at least partially by the contents of the pouch 2 are in direct physical contact with these contents, in particular the biopharmaceutical product P, and in such a way that with the inherent means of support and replacement 6 then being functionally active, the incident body C passes directly substantially between one and the other of the inherent means of support and replacement 6 and within the contents of the pouch 2 , in particular the biopharmaceutical product P.
  • the incident body C is substantially loaded on the inherent means of support and replacement 6 when it is not or should not be substantially within the biopharmaceutical product P, whereas at at least a time or stage of the production process, it is necessarily substantially within the biopharmaceutical product P.
  • the incident body C is a waste that is produced within the biopharmaceutical product P during the production process, and this waste is then captured by the inherent means of support and replacement 6 by being isolated and separated from the biopharmaceutical product P.
  • the incident body C is an activator of the process of the production of the biopharmaceutical product that is not present within the latter at the beginning of the process, but is found there subsequently, released by the inherent means of support and replacement 6 on which it is originally loaded.
  • the inherent means of support and replacement 6 consists of, or comprises, a membrane ( FIGS. 3 , 5 , 6 , 7 , 8 ) or a coating ( FIG. 4 ) or a surface treatment ( FIG. 9 ) of the wall 3 of the pouch 2 ( FIGS. 3 to 11 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ), or a support and replacement body ( FIGS. 10 ), or a support and replacement compartment ( FIG. 11 ).
  • the inherent means of support and replacement 6 is located toward the lower face 3 b of the wall 3 of the pouch 2 ( FIGS. 2 to 5 and 7 to 11 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ) that forms it or integrates it.
  • This embodiment does not exclude others, whereby the inherent means of support and replacement 6 can be located toward the outside face 3 a of the wall 3 of the pouch 2 whereas it is able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 ( FIG. 6 ).
  • the inherent means of support and replacement 6 is located on the entire surface of the face of the wall 3 of the pouch 2 ( FIGS. 3 to 6 , 8 and 9 ) or at least one port 4 ( FIG. 12 ) or functional device 5 ( FIG. 13 ), which forms it or integrates it.
  • the inherent means of support and replacement 6 is located on one portion of the surface of the face of the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or integrates it by then being either located ( FIG. 7 ) or distributed over this surface.
  • the inherent means of support and replacement 6 is located in the lower part 2 b of the pouch unit 1 or in this lower part 2 b and in all or part of the median part 2 d.
  • the inherent means of support and replacement 6 is located in the lower part 2 b of the pouch unit 1 or in this lower part 2 b and all or part of the median part 2 d.
  • the inherent means of support and replacement 6 can be located in the upper part 2 c of the pouch unit, as is the case if it is located on a port 4 such as the port 4 that is shown in FIG. 12 .
  • the inherent means of support and replacement 6 has a surface area for replacement with the contents of the pouch 2 during the process for the production of the biopharmaceutical product P that is larger than, more specially significantly larger than, more specially on the order of a multiple of, the surface area of the inside face 3 b of the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or integrates it, and that is in direct contact with the contents of the pouch 2 .
  • Such a larger surface area for replacement is obtained as a result of the composition of the inherent means of support and replacement 6 , or the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or in which it is integrated or the configuration of the inherent means of support and replacement 6 on the wall 3 of the pouch 2 or at least one port 4 or functional device 5 that forms it or in which it is integrated ( FIGS. 8 and 9 ).
  • the inherent means of support and replacement 6 is active per se, for example, because its nature makes it possible to capture or release the incident body C at any time and permanently, without requiring an action to be taken to do so.
  • the inherent means of support and replacement 6 is not active per se at any time and permanently but it requires being made active as a consequence of a dedicated activation operation.
  • the inherent means of support and replacement 6 is made active in response to the value taken on by at least one physical-biological-chemical condition of the biopharmaceutical product P or at least one physical-biological-chemical condition existing in the pouch 2 .
  • a physical-biological-chemical condition is, for example, the temperature, the pH, the composition, the contents of a certain body, the presence of a certain microorganism . . . .
  • the inherent means of support and replacement 6 is made active in response to the value not of the physical-biological-chemical condition as such, but in response to the variation of such a physical-biological-chemical condition.
  • the inherent means of support and replacement 6 is made active in response to a dedicated activation operation of a physical, biological or chemical nature, such as heat, stirring . . . .
  • means for activating the inherent means of support and replacement 6 of a physical, biological or chemical nature are provided that are structurally separate from the pouch unit 1 but are designed to be combined functionally with it during the activation of the inherent means of support and replacement 6 .
  • these activation means consist of the biopharmaceutical product P that has properties of a physical, biological or chemical nature and that can activate the inherent means of support and replacement.
  • these activation means are located outside of the pouch unit 1 or in the inside space 2 a when, for example, they consist of the biopharmaceutical product P.
  • the inherent means of support and replacement 6 is formed by a layer 7 that totally and continuously coats the inside face 3 b of the film of the wall 3 or the wall 3 itself.
  • the inherent means of support and replacement 6 has a surface area for replacement with the biopharmaceutical product P during its production and/or its preservation that is substantially equal to the surface area of the inside face 3 b of the pouch 2 of the pouch unit 1 .
  • the inherent means of support and replacement 6 is formed by a continuous coating 8 over the entire inside face 3 b of the film of the wall 3 or the wall 3 itself.
  • the inherent means of support and replacement 6 is formed by a continuous layer 9 that is sandwiched between the outside face 3 a and the inside face 3 b of the film of the wall 3 or the wall 3 itself, over the entire surface of the film, or the wall.
  • the inherent means of support and replacement 6 is formed by a layer 10 that totally and continuously coats the outside face 3 a of the film of the wall 3 or the wall 3 itself, with the film of the wall 3 or the wall 3 itself then being able to allow the replacement of the incident body C, in its entire thickness, from the inside space 2 a of the pouch 2 to the outside, and vice versa.
  • the inherent means of support and replacement 6 is formed by a layer 11 that forms a type of part (or “patch”) 11 that locally coats the inside face 3 b of the film of the wall 3 or the wall 3 itself.
  • a single such part 11 of suitable surface and shape, located at the desired spot of the film of the wall 3 or the wall 3 itself, or several parts 11 , arranged and distributed according to a suitable distribution, can be provided.
  • the inherent means of support and replacement 6 is or comprises a membrane 12 that is more or less an integral part of the film of the wall 3 or the wall 3 itself, on the inside face 3 b.
  • the membrane can be folded in a more or less significant way on itself.
  • the inherent means of support and replacement 6 is formed by crevices 13 or an irregular surface condition with recesses or cavities of the film of the wall 3 , obtained by particle bombardment, chemical attack, . . . .
  • the inherent means of support and replacement 6 has, by the very fact of the configuration that is provided thereto, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of the inside face 3 b of the pouch 2 .
  • the inherent means of support and replacement 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of the inside face 3 b of the pouch 2 .
  • the inherent means of support and replacement 6 is a solid body 14 , for example carried by the film of the wall 3 or by the wall 3 itself, over or toward the inside face 3 b.
  • the inherent means of support and replacement 6 has, in itself, a surface area for replacement with the biopharmaceutical product P during its production that is larger than the surface area of the inside face 3 b of the pouch 2 .
  • the means 6 can have a surface area for replacement on the order of several times, and even a large number of times, the surface area of the inside face 3 b of the pouch 2 .
  • the inherent means of support and replacement 6 consists of a compartment 15 that is limited by a wall 16 that makes possible the replacement between the inside and the outside of the compartment 16 .
  • the inherent means of support and replacement 6 occupies the entire surface or only a portion of the surface of the film of the wall 3 or by the wall 3 itself by being either located or distributed relative to this surface.
  • the inherent means of support and replacement 6 is formed by or integrated in a port 4 , while being, as above, able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 .
  • This embodiment includes the case where the inherent means of support and replacement 6 is formed by or integrated not directly in the port 4 itself, but indirectly, namely in an element for supporting the port 4 .
  • the inherent means of support and replacement 6 is formed by or integrated in a functional device 5 , while being, as above, able to be accessible from the inside space 2 a of the pouch 2 and in direct physical contact with the contents of the pouch 2 .
  • This embodiment includes the case where the inherent means of support and replacement 6 is formed by or integrated not directly in the functional device 5 itself, but indirectly, namely in an element for supporting the functional device 5 .
  • the process for production and the pouch unit 1 can be the object of several different embodiments relative to the time when the inherent means of support and replacement 6 is loaded with the incident body C and the time when it is not loaded with the incident body C, relative to the time before the filling of the pouch 2 and once the biopharmaceutical product P is produced.
  • the inherent means of support and replacement 6 is not loaded with the incident body C.
  • the inherent means of support and replacement 6 is substantially loaded with the incident body C.
  • the inherent means of support and replacement 6 is not loaded with the incident body C.
  • the inherent means of support and replacement 6 is substantially loaded with the incident body C.
  • the inherent means of support and replacement 6 is not loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is loaded with the incident body C.
  • This embodiment is applied, for example, with an incident body C that is an undesirable body that does not exist at the beginning of the process for the production of the biopharmaceutical product P, but is produced during this production process and that is desired to be eliminated within the biopharmaceutical product P itself.
  • the inherent means of support and replacement 6 is substantially loaded with the incident body C, and after the biopharmaceutical product P has been produced, in contrast, it is not loaded with the incident body C.
  • This embodiment that is applied, for example, with a body C can then be an incident body that is necessary to the process for the production of the biopharmaceutical product P, existing at the beginning of the production process, consumed during this process, and not existing at the end.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Sustainable Development (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Clinical Laboratory Science (AREA)
  • Packages (AREA)
  • Basic Packing Technique (AREA)
  • Bag Frames (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US13/499,738 2009-10-02 2010-09-29 Production of a biopharmaceutical product Abandoned US20120193264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0956889 2009-10-02
FR0956889A FR2950802B1 (fr) 2009-10-02 2009-10-02 Elaboration et/ou conservation d'un produit biopharmaceutique.
PCT/FR2010/052048 WO2011039472A2 (fr) 2009-10-02 2010-09-29 Elaboration d'un produit biopharmaceutique

Publications (1)

Publication Number Publication Date
US20120193264A1 true US20120193264A1 (en) 2012-08-02

Family

ID=42274539

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/499,738 Abandoned US20120193264A1 (en) 2009-10-02 2010-09-29 Production of a biopharmaceutical product

Country Status (4)

Country Link
US (1) US20120193264A1 (de)
EP (1) EP2483385A2 (de)
FR (1) FR2950802B1 (de)
WO (1) WO2011039472A2 (de)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714384A (en) * 1994-06-28 1998-02-03 Wilson; John R. Compartmentalized tissue culture bag
US5988422A (en) * 1998-07-16 1999-11-23 Stedim, Z.I. Des Paluds Sachets for bio-pharmaceutical fluid products
US20040209360A1 (en) * 2003-04-18 2004-10-21 Keith Steven C. PVA-based polymer coating for cell culture
US20050186669A1 (en) * 2004-02-20 2005-08-25 Cesco Bioengineering Co., Ltd. Apparatus and method for preparing and culturing cells
US20050239200A1 (en) * 2004-04-23 2005-10-27 Beckwith Scott W Devices for culturing anaerobic microorganisms and methods of using the same
US20060240458A1 (en) * 2005-04-04 2006-10-26 Steichen John C Flexible culture medium bag containing nutrient concentrate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557723A (en) 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4638043A (en) 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US4752478A (en) 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
AU609769B2 (en) 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
FR2767141B1 (fr) * 1997-08-08 2001-05-11 Sanofi Elf Dispositif pour la culture de bacteries lactiques
FR2795647B1 (fr) * 1999-06-30 2004-05-07 Maco Pharma Sa Ensemble de poches destine a recevoir un fluide biologique et a mettre en evidence une eventuelle contamination du fluide biologique
DE19932439C2 (de) * 1999-07-12 2002-06-13 Sefar Ag Rueschlikon Bioreaktor
DE10010950A1 (de) * 2000-03-06 2001-09-20 Sefar Ag Rueschlikon Bioreaktor und Verfahren zum Züchten dendritischer Zellen
JP2002112763A (ja) * 2000-10-10 2002-04-16 Nipro Corp 細胞培養容器
US20050205840A1 (en) * 2003-10-03 2005-09-22 Farneth William E Oxygen scavenging compositions and methods of use
EP1701780B8 (de) * 2004-01-07 2014-09-24 Pall Technology UK limited Behälter zur durchführung von biologischen prozessen enthaltend ein integriertes einblasrohr, sowie verfahren zu dessen herstellung
EP1773976B2 (de) * 2004-06-04 2020-01-01 Global Life Sciences Solutions USA LLC Einwegbioreaktorsysteme und -verfahren
US9416341B2 (en) * 2006-03-20 2016-08-16 Gusmer Enterprises, Inc. Sustained release additives for fermentation products
GB0700380D0 (en) * 2007-01-09 2007-02-14 Breath Ltd Storage Of Ampoules
JP5209433B2 (ja) 2007-10-19 2013-06-12 日東電工株式会社 貼付製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714384A (en) * 1994-06-28 1998-02-03 Wilson; John R. Compartmentalized tissue culture bag
US5988422A (en) * 1998-07-16 1999-11-23 Stedim, Z.I. Des Paluds Sachets for bio-pharmaceutical fluid products
US20040209360A1 (en) * 2003-04-18 2004-10-21 Keith Steven C. PVA-based polymer coating for cell culture
US20050186669A1 (en) * 2004-02-20 2005-08-25 Cesco Bioengineering Co., Ltd. Apparatus and method for preparing and culturing cells
US20050239200A1 (en) * 2004-04-23 2005-10-27 Beckwith Scott W Devices for culturing anaerobic microorganisms and methods of using the same
US20060240458A1 (en) * 2005-04-04 2006-10-26 Steichen John C Flexible culture medium bag containing nutrient concentrate

Also Published As

Publication number Publication date
WO2011039472A2 (fr) 2011-04-07
FR2950802B1 (fr) 2012-02-03
FR2950802A1 (fr) 2011-04-08
WO2011039472A3 (fr) 2012-03-22
EP2483385A2 (de) 2012-08-08

Similar Documents

Publication Publication Date Title
Motedayen et al. Development and characterisation of composite films made of kefiran and starch
US8877469B2 (en) Method of drying biological material
Yan et al. Effects of extrusion and glycerol content on properties of oxidized and acetylated corn starch-based films
Ma et al. Fabrication of biodegradable polymer foams for cell transplantation and tissue engineering
CA2673589C (en) Method of drying biological material
JP5344094B2 (ja) 多層フィルム、及び細胞培養容器
Moreira et al. Electrospun polymeric nanofibers in food packaging
AU2015229296A1 (en) In vivo and in vitro use of graphene
KR101931827B1 (ko) 젖산균 및 건조제를 포함하는 산물
CN114080242A (zh) 在多相生物材料上负载微生物的方法
WO2007056355A3 (en) Devices and methods for culturing, preserving, transporting, storing, reconstituting and assaying cellular materials
WO2009088023A1 (ja) 培養バッグ及び細胞培養方法
US20120193264A1 (en) Production of a biopharmaceutical product
US9296989B2 (en) Composition and method for delivery of living cells in a dry mode having a surface layer
JP2016513606A (ja) 焼成食品用のエチルアルコール放出パッケージ
JP6844260B2 (ja) 培養容器、及び培養容器の製造方法
US20210269210A1 (en) Environment protected starch container device
KR20150089904A (ko) 박토스터 알렉신을 이용한 항균 식품포장재의 제조방법 및 이에 의한 항균 식품포장재
FR3032718A1 (fr) Procede de culture microbienne mettant en œuvre un sac a analyse comprenant de la poudre de bouillon de culture
JP2006042810A (ja) 超薄型マルチウェルプレートの製造法
JP6241257B2 (ja) 培養容器、及びリンパ球の培養方法
Du et al. Porous sepiolite/starch composites: Preparation, structure and absorption properties
TW201213206A (en) A biodegradable mixture
GB2582174A (en) Environment protected starch container device
Shepard et al. Extracellular Matrix Composition Influence on Gene Delivery In Hydrogels

Legal Events

Date Code Title Description
AS Assignment

Owner name: SARTORIUS STEDIM BIOTECH S.A., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARBAROUX, MAGALI;DOREY, SAMUEL;GUENERON, MAREVA;AND OTHERS;SIGNING DATES FROM 20120323 TO 20120326;REEL/FRAME:027970/0987

AS Assignment

Owner name: SARTORIUS STEDIM FMT SAS, FRANCE

Free format text: MERGER;ASSIGNOR:SARTORIUS STEDIM BIOTECH;REEL/FRAME:031974/0578

Effective date: 20131025

AS Assignment

Owner name: SARTORIUS STEDIM FMT SAS, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 031974 FRAME 0578. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:SARTORIUS STEDIM BIOTECH;REEL/FRAME:032086/0293

Effective date: 20131025

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION